Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Abilify
|
| gptkbp:class |
Atypical antipsychotic
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
Hypersensitivity to aripiprazole
|
| gptkbp:dosage_form |
Injection
|
| gptkbp:effective_date |
2015-10-30
|
| gptkbp:frequency |
Once a month
|
| gptkbp:has_ability |
441 mg
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aristada
|
| gptkbp:ingredients |
gptkb:Aripiprazole
|
| gptkbp:invention |
2026-10-30
|
| gptkbp:is_used_for |
gptkb:Schizophrenia
|
| gptkbp:label |
FDA approved labeling
|
| gptkbp:manager |
Intramuscular injection
|
| gptkbp:manufacturer |
gptkb:Alkermes,_Inc.
|
| gptkbp:marketed_as |
gptkb:Aristada_Initio
|
| gptkbp:side_effect |
gptkb:Anxiety
gptkb:Insomnia gptkb:Nausea Weight gain Drowsiness |